Retatrutide: What to Know About the Triple-Hormone Weight Loss Drug

Retatrutide is an experimental once-weekly injectable medication being developed by Eli Lilly for obesity, type 2 diabetes, and related conditions. It belongs to a newer generation of weight loss drugs called multi-receptor agonists, meaning it activates more than one hormone pathway at the same time. Specifically, retatrutide is a triple agonist that stimulates three receptors: GLP-1, GIP, and glucagon. Because of this, it is often nicknamed the triple-G or triple-hormone drug.

To put it in context, semaglutide (Ozempic, Wegovy) targets one receptor, GLP-1. Tirzepatide (Mounjaro, Zepbound) targets two, GLP-1 and GIP. Retatrutide adds a third, glucagon, which plays a role in how the body burns energy and stores fat in the liver. The theory is that hitting three pathways could produce more weight loss than current drugs, and early data support that idea.

It is important to be clear: as of 2026, retatrutide is not FDA approved and is not available by prescription. It can only be accessed through clinical trials. The excitement comes from its Phase 2 results, but large Phase 3 trials must confirm both how well it works and how safe it is before any approval. If you are curious about how single- and dual-agonist drugs already on the market compare, that context helps explain why a triple agonist is generating attention.

In its Phase 2 trial, retatrutide produced the largest average weight loss reported for any obesity medication to date. The study (Jastreboff et al., NEJM 2023) enrolled 338 adults with obesity and tested several doses over 48 weeks. At the highest 12 mg dose, participants lost an average of 24.2% of their body weight, roughly 26 kilograms or about 58 pounds. At the 8 mg dose, average loss was about 22.8%.

These numbers are striking when compared to other drugs. In STEP 1, semaglutide produced about 14.9% average weight loss. In SURMOUNT-1, the top dose of tirzepatide produced about 20.9%. Retatrutide's roughly 24% therefore edges ahead of both, though head-to-head trials would be needed to confirm a true advantage.

One of the most notable findings was that the weight loss curve had not flattened by the end of the 48-week study, suggesting people might lose even more with longer treatment. About 26% of those on the highest dose lost at least 30% of their body weight, a level of result previously seen mostly with bariatric surgery. Still, these are Phase 2 findings in a few hundred people. The ongoing Phase 3 TRIUMPH program is testing retatrutide in much larger groups, and those results will determine whether the early promise holds, including for people working through a stubborn weight plateau on existing drugs.

Retatrutide works by mimicking three natural gut and pancreatic hormones at once, each contributing to weight loss in a different way. The first, GLP-1 (glucagon-like peptide-1), slows stomach emptying, reduces appetite, and quiets the mental chatter about food that many people call food noise. This is the same pathway used by Ozempic and Wegovy.

The second hormone, GIP (glucose-dependent insulinotropic polypeptide), also affects appetite and how the body handles fat and sugar, and it may reduce nausea caused by GLP-1 activity. This dual GLP-1 and GIP action is what tirzepatide uses. The third and newest target, glucagon, is where retatrutide stands apart. Glucagon increases energy expenditure, meaning the body burns more calories, and it helps mobilize fat stored in the liver. This may explain why retatrutide showed strong effects on liver fat in early studies.

Together, these three actions reduce how much you eat while also nudging up how much energy you burn, a combination that may drive deeper weight loss than appetite suppression alone. Researchers are especially interested in the glucagon component for treating metabolic dysfunction-associated steatotic liver disease (MASLD), a fatty liver condition tied to obesity. Understanding the underlying biology helps explain why these medications affect appetite and metabolism so broadly, not just the number on the scale.

Retatrutide's side effects in trials looked similar to other GLP-1-based drugs, with stomach and digestive issues being the most common. In the Phase 2 study (NEJM 2023), the most frequent side effects were nausea, vomiting, diarrhea, and constipation. These were mostly mild to moderate and happened most often while the dose was being gradually increased, a process called titration.

Like other drugs in this class, side effects tended to ease as people's bodies adjusted to a steady dose. Slow dose escalation is used specifically to reduce these effects. Because glucagon can raise heart rate and affect blood sugar regulation, researchers are watching cardiovascular measures and blood sugar closely in the larger Phase 3 trials. In the Phase 2 data, increases in heart rate were observed and are being studied further.

It is worth repeating that the full safety picture is not yet known. Phase 2 trials are relatively small and short. The Phase 3 TRIUMPH program, with thousands of participants over longer periods, is designed to catch less common or longer-term effects. As with all GLP-1 medications, anyone who eventually takes retatrutide would need medical supervision, attention to protein intake and muscle preservation, and regular check-ins, because rapid weight loss always carries trade-offs that need managing.

Retatrutide is not expected to be available for at least the next couple of years, because it must complete Phase 3 trials and FDA review first. As of 2026, the drug is in the TRIUMPH Phase 3 program, a series of large trials studying retatrutide for obesity, type 2 diabetes, knee osteoarthritis tied to obesity, and fatty liver disease. These trials typically run for one to two years, and results must be submitted to regulators before any approval.

Drug development timelines are hard to predict. Even with strong results, the FDA review process takes additional months after trials finish. So while retatrutide looks promising, no one can give a guaranteed launch date, and you should be cautious about any source claiming you can buy it now. Products marketed as retatrutide outside of clinical trials are not legitimate approved medications and may be unsafe.

In the meantime, several effective approved options already exist, and more are coming, including oral GLP-1 pills now in late-stage testing. If you are considering treatment today, the best step is to talk with a qualified provider about approved medications that fit your health profile, rather than waiting for a drug that may still be years away. Staying informed about the pipeline is useful, but current approved tools can already deliver meaningful results when paired with nutrition, movement, and support.